Here’s a look at FDA’s COVID-19 vaccine review process

Pfizer, Moderna submit applications for emergency use authorization of vaccines

A look inside FDA's COVID vaccine review process

Scientists with the U.S. Food and Drug Administration (FDA) are working to review two COVID-19 vaccines submitted by drug companies Pfizer and Moderna.

Pfizer submitted its application on Nov. 20 for an emergency use authorization to the FDA Center for Biologics Evaluation and Research (CBER).

“The safety profile of a vaccine that’s going to be deployed in millions of people has to be incredibly clean,” said Dr. Peter Marks, who directs CBER. “We, as an agency, are one of the last agencies in the world that we still actually get the primary data. We don’t get summary data.”

CBER receives raw data on all participants in a vaccine trial, in addition to volumes of information on every aspect of the vaccine.

“The company can do its analysis on the patients, and we have the ability because we have the data to do our own analyses and make sure they match up,” Marks said.

Questions about coronavirus (COVID-19)? Ask Dr. McGeorge

Watch the full report in the video posted above.

About the Author:

Dr. McGeorge can be seen on Local 4 News helping Metro Detroiters with health concerns when he isn't helping save lives in the emergency room at Henry Ford Hospital.